Literature DB >> 19454469

Small-cell lung cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

M Sørensen1, E Felip.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19454469     DOI： 10.1093/annonc/mdp133

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  7 in total

Review 1.  Screening for lung cancer using low-dose spiral CT: 10 years later, state of the art.

Authors:  M Zompatori; M Mascalchi; F Ciccarese; N Sverzellati; U Pastorino
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

2.  miR-495 promotes the chemoresistance of SCLC through the epithelial-mesenchymal transition via Etk/BMX.

Authors:  Ting Wei; Weiliang Zhu; Shun Fang; Xiangpin Zeng; Jie Huang; Jie Yang; Jian Zhang; Linlang Guo
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

3.  A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.

Authors:  James D Smith; Diane L Reidy; Karyn A Goodman; Jinru Shia; Garrett M Nash
Journal:  Ann Surg Oncol       Date:  2014-04-24       Impact factor: 5.344

4.  Clinical features and prognostic factors of small cell lung cancer: A retrospective study in 148 patients.

Authors:  Qian Cai; Hong-Lan Luo; Xi-Can Gao; Chun-Jin Xiong; Fan Tong; Rui-Guang Zhang; Yu Hu; Gang Wu; Xiao-Rong Dong
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2016-12-07

5.  Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01).

Authors:  C Le Péchoux; A Laplanche; C Faivre-Finn; T Ciuleanu; R Wanders; D Lerouge; R Keus; M Hatton; G M Videtic; S Senan; A Wolfson; R Jones; R Arriagada; E Quoix; A Dunant
Journal:  Ann Oncol       Date:  2010-12-07       Impact factor: 32.976

6.  Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.

Authors:  Ahmed Salem; Hitesh Mistry; Matthew Hatton; Imogen Locke; Isabelle Monnet; Fiona Blackhall; Corinne Faivre-Finn
Journal:  JAMA Oncol       Date:  2019-03-14       Impact factor: 31.777

7.  Oral treatment with etoposide in small cell lung cancer - dilemmas and solutions.

Authors:  Renata Rezonja; Lea Knez; Tanja Cufer; Ales Mrhar
Journal:  Radiol Oncol       Date:  2013-02-01       Impact factor: 2.991
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.